Literature DB >> 25349806

Effects of moxifloxacin exposure on the conjunctival flora and antibiotic resistance profile following repeated intravitreal injections.

Mustafa Ataş1, Burhan Başkan1, Ayşe Ozköse1, Fatma Mutlu Sarıgüzel2, Süleyman Demircan1, Emine Pangal1.   

Abstract

AIM: To evaluate the effects of moxifloxacin exposure on the conjunctival flora and antibiotic resistance profile following repeated intravitreal injections.
METHODS: Seventy-two eyes of 36 patients [36 eyes in control group, 36 eyes in intravitreal injection (IVI) group] were enrolled in the study. All the eyes had at least one IVI and had diabetic macular edema (DME) or age-related macular degeneration (ARMD). Moxifloxacin was prescribed to all the patients four times a day for five days following injection. Conjunctival cultures were obtained from the lower fornix via standardized technique with every possible effort made to minimize contamination from the lids, lashes, or skin. Before the application of any ophthalmic medication, conjunctival cultures were obtained from both eyes using sterile cotton culture. An automated microbiology system was used to identify the growing bacteria and determine antibiotic sensitivity.
RESULTS: The bacterial cultures were isolated from 72 eyes of 36 patients, sixteen of whom patients (44.4%) were male and twenty (55.6%) were female. Average age was 68.4±9.0 (range 50-86). The average number of injections before taking cultures was 3.1+1.0. Forty-eight (66.7%) of 72 eyes had at least one significant organism. There was no bacterial growth in 8 (20.5%) of IVI eyes and in 16 (44.4%) of control eyes (P=0.03). Of the bacteria isolated from culture, 53.8% of coagulase negative staphylococci (CoNS) in IVI eyes and 47.2% CoNS in control eyes. This difference between IVI eyes and control eyes about bacteria isolated from culture was not statistically significant (P=0.2). Eleven of 25 bacteria (44.0%) isolated from IVI eyes and 11 (57.9%) of 19 bacteria isolated from control eyes were resistant to oxacillin. The difference in frequency of moxifloxacine resistance between two groups was not statistically significant (12.0% in IVI eyes and 21.1% in control eyes) (P=0.44). There were no cases of resistance to vancomycin, teicoplanin and linezolid.
CONCLUSION: There was no difference in species of bacteria isolated from cultures, or in the frequency of resistance to antibiotics between eyes that had recurrent IVI followed by moxifloxacin exposure compared with control eyes. However, the number of eyes that had bacterial growth was higher in IVI group than in the control group.

Entities:  

Keywords:  endopthalmitis; intravitreal injection; moxifloxacin

Year:  2014        PMID: 25349806      PMCID: PMC4206894          DOI: 10.3980/j.issn.2222-3959.2014.05.21

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  31 in total

1.  Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povidone-iodine 5.0% alone to reduce bacterial colonization in the conjunctival sac.

Authors:  Orly Halachmi-Eyal; Orly Halachimi-Eyal; Yaron Lang; Yoram Keness; Dan Miron
Journal:  J Cataract Refract Surg       Date:  2009-12       Impact factor: 3.351

2.  Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection.

Authors:  Eugene Milder; James Vander; Chirag Shah; Sunir Garg
Journal:  Ophthalmology       Date:  2012-03-13       Impact factor: 12.079

3.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Rishi P Singh; Zhengrong Li; Sarah Gray; Namrata Saroj; Amy Chen Rundle; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2010-04-09       Impact factor: 12.079

4.  Changes in ocular flora in eyes exposed to ophthalmic antibiotics.

Authors:  Sarita B Dave; Hassanain S Toma; Stephen J Kim
Journal:  Ophthalmology       Date:  2013-02-13       Impact factor: 12.079

5.  Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.

Authors:  Vincent A Deramo; James C Lai; David M Fastenberg; Ira J Udell
Journal:  Am J Ophthalmol       Date:  2006-09-20       Impact factor: 5.258

6.  Antibiotic resistance of conjunctiva and nasopharynx evaluation study: a prospective study of patients undergoing intravitreal injections.

Authors:  Stephen J Kim; Hassanain S Toma; Narinder K Midha; Edward F Cherney; Franco M Recchia; Terrence J Doherty
Journal:  Ophthalmology       Date:  2010-07-24       Impact factor: 12.079

7.  Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.

Authors:  Seenu M Hariprasad; Kevin J Blinder; Gaurav K Shah; Rajendra S Apte; Brett Rosenblatt; Nancy M Holekamp; Matthew A Thomas; William F Mieler; Jingduan Chi; Randall A Prince
Journal:  Arch Ophthalmol       Date:  2005-01

8.  Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.

Authors:  Abdhish R Bhavsar; Joseph M Googe; Cynthia R Stockdale; Neil M Bressler; Alexander J Brucker; Michael J Elman; Adam R Glassman
Journal:  Arch Ophthalmol       Date:  2009-12

9.  Prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member survey.

Authors:  David F Chang; Rosa Braga-Mele; Nick Mamalis; Samuel Masket; Kevin M Miller; Louis D Nichamin; Richard B Packard; Mark Packer
Journal:  J Cataract Refract Surg       Date:  2007-10       Impact factor: 3.351

10.  Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.

Authors:  Suman Pilli; Athanasios Kotsolis; Richard F Spaide; Jason Slakter; K Bailey Freund; John Sorenson; James Klancnik; Michael Cooney
Journal:  Am J Ophthalmol       Date:  2008-03-10       Impact factor: 5.258

View more
  2 in total

1.  Hydration of small leaking corneal perforations with cefuroxime.

Authors:  Gilad Allon; Yinon Shapira; Itzchak Beiran; Eytan Z Blumenthal
Journal:  Int Ophthalmol       Date:  2019-02-01       Impact factor: 2.031

2.  Hydration with Cefuroxime-a method for sealing a small leaking corneal perforation.

Authors:  Gilad Allon; Itzchak Beiran; Eytan Z Blumenthal
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.